Lavipharm S.A. Logo

Lavipharm S.A.

Develops & distributes Rx/OTC medicines, supplements & cosmetics for key therapeutic areas.

LAVI | AT

Overview

Corporate Details

ISIN(s):
GRS246003008
LEI:
213800USC69CRPRGWJ15
Country:
Greece
Address:
AGIAS MARINAS STR, 19002 PAIANIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lavipharm S.A. is an integrated international healthcare company focused on the research, development, manufacturing, marketing, and distribution of pharmaceutical products. The company's portfolio includes prescription (Rx) and over-the-counter (OTC) medicines, as well as food supplements and cosmetics. Lavipharm provides innovative treatment options to healthcare professionals, concentrating on key therapeutic areas such as cardiology, neurology (CNS), urology, oncology, and chronic pain. The company manages the entire value chain, from initial research and development to commercial sales and distribution.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 19:39
Interim Report
Οικονομική έκθεση LAVIPHARM Α.Ε. (2025,Εξαμηνιαία,Ενοποιημένη)
Greek (modern) 2.2 MB
2025-09-18 16:50
Earnings Release
ΔΕΛΤΙO ΤΥΠΟΥ ΟΙΚΟΝΟΜΙΚΑ ΑΠΟΤΕΛΕΣΜΑΤΑ Α΄ ΕΞΑΜΗΝΟΥ 2025
Greek (modern) 156.3 KB
2025-09-18 16:50
Earnings Release
FINANCIAL RESULTS PRESS RELEASE FIRST HALF 2025
English 99.2 KB
2025-07-10 09:38
Registration Form
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 5 η’) αναφορ…
Greek (modern) 216.3 KB
2025-07-09 09:52
Share Issue/Capital Change
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 4 θ΄) αναφορ…
Greek (modern) 205.1 KB
2025-07-03 18:12
Notice of Dividend Amount
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΠΟΚΟΠΗΣ ΔΙΚΑΙΩΜΑΤΟΣ ΜΕΡΙΣΜΑΤΟΣ / ΠΛΗΡΩΜΗΣ ΜΕΡΙΣΜΑΤΟΣ/ ΠΡΟΜΕΡΙΣΜΑΤ…
Greek (modern) 555.0 KB
2025-07-03 18:00
Post-Annual General Meeting Information
ΔΕΛΤΙΟ ΤΥΠΟΥ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Greek (modern) 123.4 KB
2025-07-03 18:00
Post-Annual General Meeting Information
PRESS RELEASE
English 121.3 KB
2025-07-03 17:35
Post-Annual General Meeting Information
ΑΝΑΚΟΙΝΩΣΗ ΕΠΙΤΡΟΠΗΣ ΕΛΕΓΧΟΥ
Greek (modern) 503.0 KB
2025-07-03 17:17
Board/Management Information
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΛΛΑΓΗΣ ΣΥΝΘΕΣΗΣ ΔΙΟΙΚΗΤΙΚΟΥ ΣΥΜΒΟΥΛΙΟΥ
Greek (modern) 598.1 KB
2025-07-03 17:05
Post-Annual General Meeting Information
ΑΝΑΚΟΙΝΩΣΗ ΓΙΑ ΤΙΣ ΑΠΟΦΑΣΕΙΣ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
Greek (modern) 195.1 KB
2025-06-11 16:30
Pre-Annual General Meeting Information
ΠΡΟΣΚΛΗΣΗ ΣΕ ΤΑΚΤΙΚΗ ΓΕΝΙΚΗ ΣΥΝΕΛΕΥΣΗ
Greek (modern) 191.0 KB
2025-05-15 16:19
Earnings Release
Βασικά Οικονομικά Μεγέθη A Τριμήνου 2025
Greek (modern) 118.2 KB
2025-05-15 16:19
Earnings Release
Financial Results Q1 2025
English 92.6 KB
2025-04-24 16:39
Investor Presentation
ΑΝΑΚΟΙΝΩΣΗ ΓΙΑ ΕΝΗΜΕΡΩΣΗ ΕΙΣΗΓΜΕΝΗΣ ΠΡΟΣ ΑΝΑΛΥΤΕΣ
English 1.0 MB

Automate Your Workflow. Get a real-time feed of all Lavipharm S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Lavipharm S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea 217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden KARO
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea 038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea 256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan 4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland KNRS
KISSEI PHARMACEUTICAL CO.,LTD. Logo
Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.
Japan 4547

Talk to a Data Expert

Have a question? We'll get back to you promptly.